Market Trends of Global Hormone Replacement Therapy Industry
This section covers the major market trends shaping the Hormone Replacement Therapy Market according to our research experts:
The Menopause Segment is Expected to Register a Healthy CAGR over the Forecast Period
Menopause is the time that marks the end of women's menstrual cycles. It is diagnosed after a woman had gone 12 months without a menstrual period. Menopause can happen at an age ranging between 40 to 50 years. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for many elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.
This application is expected to rise in the future as the geriatric population globally is increasing. As women reach the end of the reproductive stage, the estrogen levels lower, leading to mood swings, depression, anxiety, and certain physical changes. Hormone replacement therapy, with estrogen hormone, plays a vital role in combating the complications associated with menopause in the aging women population.
According to the research article titled 'Prevalence and risk factors for menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study' published in November 2021, the prevalence of menopausal symptoms was 9.3% (303/3,256), 23.9% (293/1,227), and 21.5% (405/1,881) in the reproductive stage, menopausal transition, and postmenopausal stage. Similarly, an article titled 'The Demographic Changes of Menopausal and Geripausal Women in Korea' published in February 2021, in 2030, one-fourth of elderly women who are female is expected to be postmenopausal, and nearly half of females will be. The percentage of postmenopausal women in the total female population will rise to 59.8% by 2060. Hence, a combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT) is usually suggested for treating the symptoms of menopause during the menopausal transition.
Additionally, the rise in product approvals is expected to drive the segment growth. For instance, in September 2021, Theramex announced the approval of Bijuva / Bijuve across Europe and the UK. Bijuva, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule. Similarly, in December 2020, the US FDA approved the Myovant Sciences' Orgovyx (relugolix), which is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thus leading to the reduction in the amount of testosterone produced by the testicles. This aids in the treatment of adult patients with advanced prostate cancer.
Thus, owing to the aforementioned factors, the menopause indication segment is expected to witness significant growth over the forecast period.
North America Holds the Largest Market Share, and it is Expected to do the Same Over the Forecast Period
The rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy market in the North American region, especially in the United States and Canada.
According to the National Institutes of Health (NIH), almost half of all post-menopausal women in the United States reported using HRT at least once in their lives. Also, according to a research article published in Statpearls, 2021, nearly 1.3 million American women enter the menopause phase each year in the United States. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the United States for menopausal VMS treatment and osteoporosis prevention.
Additionally, as per the American Thyroid Association (ATA), data updated in 2022, more than 12% of the population in the United States is predicted to experience a thyroid disorder during their lifetime, and nearly 20 million Americans are affected by some form of thyroid disease every year. Thus, the high incidence of thyroid hormone imbalance among the population in the United States is expected to boost the studied market in the region.
Also, in June 2022, Astellas Pharma Inc. announced a New Drug Application (NDA) for fezolinetant submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. Thus, the high trend of product approvals is also expected to drive the studied market in the region.
Overall, the market for HRT in North America is scheduled for high growth over the forecast period. The major drivers of this market are expected to increase the adoption of HRT among women for both post-menopausal and menopause management.
